# ACT Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/act-biotech

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.actbiotech.com
- Total disclosed funding: $6.6M
- Latest round: Series A (May 6, 2008)
- Investors on record: 1

## About

ACT Biotech specializes in biotechnology solutions that enhance health outcomes through innovative applications in drug development, genetic research, and personalized medicine.Established in 2008, ACT Biotech operates in the biotechnology sector, focusing on innovative solutions for health challenges. The company is headquartered in San Francisco, US, and has secured a total of USD 0.50 mn in funding over multiple rounds. In June 2010, ACT Biotech raised USD 1 mn in VENTURE DEBT. The founder's historical background is not specified.ACT Biotech is primarily engaged in the biotechnology sector, focusing on the development and provision of innovative biotechnology solutions aimed at enhancing health outcomes. The company’s core product offerings revolve around advanced biotechnological applications that address critical challenges in health, including drug development, genetic research, and personalized medicine. ACT Biotech's products are designed to serve a diverse clientele, including research institutions, pharmaceutical companies, and healthcare providers, who utilize these solutions to improve patient care and streamline research processes. The company's offerings are positioned in global markets, particularly in North America, Europe, and Asia, catering to a broad spectrum of end users ranging from healthcare professionals to researchers in academic and clinical settings.The revenue model for ACT Biotech is structured around a combination of direct sales and strategic partnerships with healthcare organizations and research institutions. The company typically engages in B2B transactions, providing its biotechnology products and services through tailored agreements that meet the specific needs of its clients. For example, it may offer subscription-based access to its proprietary technology platforms or enter into collaborative research agreements that involve milestone payments contingent upon the achievement of specific project goals. Pricing structures for these transactions are designed to reflect the value and innovation of the products offered, with services potentially including long-term contracts or one-time licensing fees for flagship products. This diversified approach to revenue generation enables ACT Biotech to effectively support its operational needs while fostering long-term relationships within the biotechnology ecosystem.Following its most recent funding round in June 2010, where ACT Biotech raised USD 1 mn in VENTURE DEBT, the company plans to utilize these resources to further develop its product offerings. ACT Biotech aims to launch new biotechnology solutions specifically designed to address unmet needs in personalized medicine by the end of 2011. Additionally, the company has targeted expansion into new markets, focusing on Asia and Europe, by 2012, to broaden its reach in the global biotechnology landscape.

## Funding rounds

- Series A, May 6, 2008, $6.6M — NGN Capital

## Investors

- NGN Capital (https://capitalatlas.ai/funds/ngn-capital) — Series A